Vaxart Inc (VXRT)
$0.96
0.06 (6.00%)
VXRT Stock Quote Delayed 30 Minutes
VXRT Stock Earnings: Vaxart Meets EPS, Beats Revenue for Q1 2024
VXRT stock results show that Vaxart met analyst estimates for earnings per share but beat on revenue for the first quarter of 2024.
Top 5 Stocks for 2024
INSIDE: Investing legend Louis Navellier reveals his Top 5 Stocks for 2024 — FREE!
Download His Free Report Here:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
-
Market Cap
145.71M
PE Ratio
-5.64
EPS
-0.17
Volume (Avg. Vol.)
1.57M
Day's Range
$0.95 - $1.04
52-Week Range
$0.53 - $1.54
Dividend & Yield
N/A (N/A)
VXRT Stock Predictions, Articles, and Vaxart Inc News
Why Is Vaxart (VXRT) Stock Down 25% Today?
Vaxart (VXRT) stock is taking a beating on Wednesday as investors react to the company announcing a proposed public share offering.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
We're starting the day off right with a breakdown of the biggest pre-market stock movers worth reading about on Wednesday!
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
We're starting off the day with a breakdown of the biggest pre-market stock movers traders need to know about on Wednesday!
What Is Going on With Vaxart (VXRT) Stock Today?
Vaxart released encouraging results for its oral Covid-19 vaccine, though sentiment for VXRT stock presently remains mixed.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Good morning! We're starting off another busy day of trading with a breakdown of the biggest pre-market stock movers for Tuesday!
Vaxart: Oral Covid-19 Vaccine Is Interesting, But Questions Linger
VXRT stock is more than a Covid-19 meme trade. But is there enough fundamentals there to support an investment heading into 2022?
Vaxart Deserves More Respect on Wall Street for Its Promising Covid-19 Vaccine
As the Covid-19 vaccine maker expands into a second manufacturing facility, VXRT stock remains an undervalued gem.
VXRT Stock: Other Vaccine Stocks Are Gaining But Jim Cramer Just Sent Vaxart Down
Despite a new factory acquisition, VXRT stock is down 9% on the day as 'Mad Money' host Jim Cramer warns investors about Vaxart.
Don’t Write Off Vaxart, As Its Oral Vaccine Still Has a Chance
VXRT stock is still worth a shot, as there's still big potential demand for a "no-needle" Covid-19 vaccine alternative.
Why Investing in VXRT Stock is a Coin Flip
Vaxart is a gamble for biotechnology investors, with its upside too dependent on the approval of an oral vaccine.
Vaccine Stocks: Why MRNA, VXRT, CVAC and NVAX Stocks Need a Band-Aid Today
Today, vaccine stocks are taking a massive hit as investors price in the potential effect of oral medications for Covid-19 on this sector.
Vaxart Traders Should Not Dismiss the Vaccine Maker’s Momentum
The recently range-bound price action of VXRT stock doesn't reflect the progress that Vaxart is making against Covid-19.
It’s Time to Start Thinking Seriously About Vaxart
While VXRT stock is risky due to underlying clinical challenges, the evolving nature of Covid-19 makes it worth consideration.
Vaxart Stock Is One Vaccine Also-Ran Worth Another Look
If you're looking to wager on a vaccine long-shot, place your bet on VXRT stock.
Is Vaxart Stock Really Worth a Shot?
VXRT stock still has hope as Vaxart is developing modern rDNA vaccines in pill form (including a Covid-19 vaccine), aiming to overcome needle challenges.
Longshot Covid Play Vaxart Stock Is Too Risky at These Prices
Vaxart got approval Aug. 2 for a Phase II trial for its oral Covid-19 vaccine. VXRT stock has gained 22% since. Should you buy on momentum?
Vaxart Is Another Risky Biotech Stock to Avoid Right Now
VRXT stock is highly overvalued. Investors are holding out for its Covid-19 vaccine, but it may not be approved in time to boost shares.
